SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD. Topline clinical data from SOL-1 expected in Q4 2025. Active clinical trial sites enrolling patients directly in ...

© 2024 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.